|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's Range||0.1020 - 0.1090|
|52 Week Range||0.0290 - 0.6580|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 15, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol ("CBD") (the "Serum") on skin hydration.Table 2To view an enhanced version of Table 2, please visit:https://orders.newsfilecorp.com/files/6922/63880_98aa5e38b4389924_002full.jpgThe study was conducted by an independent ...
Toronto, Ontario--(Newsfile Corp. - September 14, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), announces that its board of directors has agreed to amend the terms of certain common share purchase warrants (the "Warrants") held by Tamar Innovest Ltd. (formerly, Solsken Ltd.) ("Tamar").The Warrants were issued by the Company on April 15, 2019 and consist of: (a) 13,981,916 Warrants at an exercise price of US $0.1252 expiring April 15, ...
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on the Company. The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action. Mackie Research's ...